“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Published Sep 13, 2024 12:15pm EDT ...

Its primary purpose is treatment, ensuring a robust evaluation of Dupilumab’s efficacy and safety. The study began on January 3, 2024, with primary completion expected in 2025.

Dupilumab provides effective therapy for those who have failed other modalities, but it should not be considered first-line therapy for a number of reasons. First, it is costly.

Dupilumab was added as an active comparator in the trial because its efficacy has been shown in this population and it was previously evaluated in a similarly designed proof-of-concept study. 6,7 ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Infants and young children with atopic dermatitis experienced improvements in signs and symptoms with dupilumab treatment regardless of other type 2 comorbidities, according to a study published ...

Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine, 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 ...

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 ...

Dupilumab reduced biomarkers associated with Th2-driven inflammation. Injection-site reactions, nasopharyngitis, nausea, and headache occurred more frequently with dupilumab than with placebo.